The Global Action Network for Sickle Cell & Other Inherited Blood Disorders (GANSID)
The Gap: Whether operating in a low, medium, or high-resource environment, most advocates and organizations supporting individuals and families affected by inherited blood disorders are typically motivated by a personal connection to the disease. This ensures a passionate commitment, but may not provide access to the opportunities or resources needed for effective advocacy. With cross-disease collaboration, Inherited Blood Disorders serving organizations would be able to work together to reach and effectively advocate for more patients especially those living in low and medium-resource countries.
The Opportunity: The Global Action Network for Sickle Cell & Other Inherited Blood Disorders (GANSID) was incorporated under the laws of the State of Delaware, United States of America, on January 18th, 2022 to unite the forces of organizations serving inherited blood disorders to better amplify their impact globally.
It was established to identify common purposes among inherited blood disorders and embark on cross-disease while lending its voice to disease-specific advocacy initiatives to meet the needs of people living with inherited blood disorders no matter where they live in the world.
The GANSID would especially bring the voices of inherited blood disorders together to advance care, treatment, research, capacity building, and education in regions of the world facing acute challenges due to underdeveloped healthcare systems, poverty, and a lack of disease awareness among patient populations.
To shape and advance efforts that ensure the promise of new inherited blood disorders innovation can be fully realized for all patients, the Global Action Network for Sickle Cell & Other Inherited Blood Disorders will strengthen the advocacy skill sets of the patient organizations serving the inherited blood disorders communities through training, mentorship, and cross-disease collaborations.
Who We Are: A global network of patient organizations, health care providers, health organizations, researchers, professional and academic societies, and industry partners that serve people impacted by sickle cell disease (SCD) and other inherited blood disorders.